AI-Generated Summary

Natco Pharma has won a significant patent battle against Roche in the Delhi High Court, enabling the immediate launch of its generic version of risdiplam, a critical drug for spinal muscular atrophy (SMA). This ruling dramatically reduces the cost of the life-saving treatment, making it vastly more accessible to Indian patients. The decision highlights the complex interplay of intellectual property, public interest, and drug affordability in emerging markets.

In a nutshell

This court ruling sets a precedent for patent enforcement and drug access in India, potentially influencing pharmaceutical strategies for rare disease drugs globally, particularly concerning market entry and pricing in developing nations. It underscores the ongoing tension between innovator intellectual property rights and the imperative for affordable healthcare solutions.

Source: The Economic Times